Stanford phd candidate Calvin schmidt posts about investing opportunities in synthetic biology. Available for consulting on potential investments in this area.

Calvin Schmidt Synthetic Biology Index: August Update

Performance overview

Value at beginning of month: $156,453.21

Value at end of month: $168,637.53

Month over month change: +7.79%

Total IRR: 37.67%

Related indices, monthly change

NASDAQ: +4.81%

IVV (iShares Core S&P 500): +3.20%

IBB (iShares NASDAQ Biotechnology Index): +5.87%

MXI (iShares Global Materials): -2.63%

VEGI (iShares MSCI Global Agriculture Producers): +0.76%

ICLN (iShares Clean Energy): -4.18%

Individual performances


August was extremely good for the index, outperforming all comps in the general market. The performance wasn’t driven by any single company; there were many with 20% - 30% gains. Leading the pack was uniQure, which grew news that they started dosing for its lead compound’s phase 2b trial. Another company to watch is Codexis, which continued its phenomenal year with another good month, growing another 25% in August and approaching a $1 billion market cap for the first time ever. This company has gained almost $600 million in value since the beginning of the year.

Changes made to index


You can view the index here.

Allocation as of September 17, 2018


Calvin Schmidt Synthetic Biology Index: September Update

Calvin Schmidt Synthetic Biology Index: July Update